id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0610-0020,FDA,FDA-2008-D-0610,Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic - Guidance for Industry,Other,Guidance,2020-05-08T04:00:00Z,2020,5,2020-05-08T04:00:00Z,,2024-12-18T13:51:32Z,,1,0,0900006484591e76
FDA-2008-D-0610-0018,FDA,FDA-2008-D-0610,"Postmarketing Adverse Event Reporting for Medical Products and Dietary
Supplements During a Pandemic; Guidance for Industry",Other,Guidance,2020-03-19T04:00:00Z,2020,3,2020-03-19T04:00:00Z,,2024-11-12T23:18:22Z,,1,0,0900006484465441
FDA-2008-D-0610-0017,FDA,FDA-2008-D-0610,Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic; Guidance for Industry,Other,,2020-03-19T00:00:00Z,2020,3,,,2020-04-21T06:12:28Z,,0,1,090000648445772a